DEA Targets Three New Mitragynine Compounds for Schedule I
Published Date: 7/6/2026
Proposed Rule
Summary
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Possession Becomes a Schedule I Offense
If you possess mitragynine pseudoindoxyl, MGM-15, or MGM-16 after the temporary order is published, you will be subject to Schedule I rules and the CSA's civil and criminal penalties. The temporary order will take effect on the date it is published in the Federal Register (to be published on or after August 5, 2026) and impose schedule I controls.
Researchers Face Schedule I Requirements
If you conduct research, instructional activities, or chemical analysis with mitragynine pseudoindoxyl, MGM-15, or MGM-16, those activities will be subject to Schedule I regulatory controls and associated administrative requirements and sanctions once the temporary order is published. The temporary order will take effect on its publication date (on or after August 5, 2026).
Retailers and Vendors Lose Legal Market Access
Retailers, online vendors, vape shops, gas stations, and other sellers of products containing these chemicals will be subject to Schedule I prohibitions on manufacture and distribution when the temporary order is published. Selling or distributing these substances will trigger the CSA's criminal and civil sanctions.
Temporary Scheduling Period Set (2 + 1 Years)
The temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I will remain in effect for two years from the order's publication date, with a possible one-year extension if regular scheduling proceedings are initiated. The DEA intends to publish the temporary scheduling order on or after August 5, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-13580, Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Next: 2026-13586, Registering NFA Firearms That Fall Out of Government Contract
If you make special firearms for the U.S. Government and your contract ends, you’ll now have a new way to register those guns even if you missed the usual deadline. This change helps manufacturers avoid penalties and keeps everything clear and fair. Comments on this proposal are open until September 4, 2026, so don’t miss your chance to weigh in!